TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: ORal IrON Supplementation With Ferric Maltol in Patients With Heart Failure Carrying Left Ventricular Assist Devices

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Signed written informed consent prior to any study-related procedure and willingness to comply with treatment and follow-up procedures~2. Male and female patients ≥18 years at day of inclusion~3. Patients capable of understanding the investigational nature, potential risks and benefits of the clinical trial~4. Patients that have an LVAD implanted for chronic heart failure and which are clinically stable for at least 6 months after LVAD implantation in the opinion of the investigator~5. 6 min walk distance \>50 m~6. Mild-to-moderate iron-deficiency anemia as defined by a hemoglobin concentration ≥7 g/dl and \<12 g/dl in females or ≥8 g/dl and \<13 g/dl in males, and serum ferritin \<100 µg/l, or 100-300 µg/l and transferrin saturation \<20% at screening~7. Women of childbearing potential must:~Have a negative pregnancy test at screening Agree to use reliable methods of contraception during the course of the study~Exclusion Criteria:~1. Active hematological disorders other than iron-deficiency anemia~2. Other medical condition that according to the investigator's assessment is causing or contributing to anemia~3. Active malignancy~4. Active infectious disease~5. Active bleeding~6. Severe renal insufficiency (requiring dialysis)~7. Severe liver injury as indicated by serum aminotransferases \>3 x upper limit of normal or bilirubin levels \>50 µmol/l~8. Ongoing oral or intravenous iron supplementation~9. Concomitant erythropoietin medication~10. Pregnancy or lactation period~11. Subject has received any investigational medication or any investigational devices within 30 days prior to the first dose of study medication or is actively participating in any investigational drug/ devices trial, or is scheduled to receive investigational drug/devices during the course of the study.~12. Known or suspected hypersensitivity to any of the active substances or any excipients of the investigational medicinal product~13. Known haemochromatosis or other iron overload syndromes~14. Patients who have been receiving repeated (\>1) blood transfusions during the past 6 months

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Ferric maltol 30 mg (Feraccru®) (Type: EXPERIMENTAL): Treatment with Feraccru® 30 mg hard capsules (Ferric maltol 30 mg). One capsule twice daily, morning and evening, on an empty stomach for 12 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Safety Study of TAK-128 in Subjects With Diabetic Peripheral Neuropathy

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Has successfully completed protocol 01-04-TL-128-003.~* Female subjects of childbearing potential must be nonpregnant, nonlactating and on an acceptable form of contraception.~* Must be in good health at Enrollment, as determined by a physician at the Month 6 Visit of Protocol 01-04-TL-128-003 (ie, via medical history and physical examination).~* Has clinical laboratory evaluations within the normal reference range for the testing laboratory, unless the results are deemed not clinically significant by the investigator or sponsor, at the Month 6 Visit of Protocol 01-04-TL-128-003.~* Has a creatinine level less than or equal to 2 mg/dL or 176.8 umol/L.~* The subject is willing to follow an American Diabetes Association or similar recommended dietary regimen.~Exclusion Criteria:~* Has developed other neuropathies due to causes other than diabetes such as alcohol abuse liver or renal disease, uremia, toxic exposure, genetic factors, inflammatory demyelinating diseases, monoclonal gammopathies; or endocrine, metabolic or nutritional disorders (included treated or untreated pernicious anemia).~* Has a systolic blood pressure greater than 160 mm HG or diastolic blood pressure is greater than 95 mm HG.~* The subject has an alanine aminotransferase level of greater than 1.5 times the upper limit of normal, active liver disease, or jaundice.~* Has a significant, actively treated or unstable pulmonary, cardiovascular, gastrointestinal, hepatic, hematologic, musculoskeletal, or endocrine (other than diabetes mellitus or stably treated hypothyroidism) disease.~* Cannot use any of the following prescription medications throughout the duration of the study, including:~  * Lipoic acid.~ * Linolenic acid (primrose oil).~ * Inositol.~ * Topiramate.~ * Acetyl-L-Carnitine.~ * Nerve growth factors.~ * Capsaicin.~* Has any other serious disease or condition at the Month 6 Visit of Protocol 01-04-TL-128-003 or at the Baseline/Rollover Visit that might affect life expectancy or make it difficult to successfully manage and follow the subject according to the protocol.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- TAK-128 100 mg QD (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Imatinib Mesylate and Mycophenolate Mofetil for Steroid-Refractory Sclerotic/Fibrotic cGVHD in Children

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion criteria~* Patients must have a diagnosis of chronic GVHD with fibrotic/scleroderma-like features. This diagnosis can be made clinically or by histopathology.~* Patients must have active disease with at least one of the following manifestations: skin sclerosis, symptomatic bronchiolitis obliterans, extensive lung fibrosis, pathologically demonstrated visceral fibrotic involvement of the gut.~* Patients with corticosteroid refractory or dependant cGVHD are eligible. Steroid-refractory chronic GVHD is defined as chronic GVHD of sustained severity during the last full month during which the patients received the equivalent of prednisone 0.5 mg/kg or more per day or 1 mg/kg or more every other day.~* Age under 21 years old~Exclusion criteria~* Patients who have had chemotherapy, radiotherapy within 4 weeks prior to entering the study.~* Patients who have not recovered from adverse events.~* Prior treatment with imatinib mesylate or other tyrosine kinase inhibitor after the date of transplant.~* Patients on pregnancy or lactating

- Gender: ALL
- Minimum Age: None
- Maximum Age: 21 Years
- Healthy Volunteers: f

Study Arms:
- Imatinib mesylate, Mycophenolate mofetil (Type: EXPERIMENTAL): MMF 15-20mg/kg (Max 1 g) bid + Imatinib mesylate qd~* Dose of imatinib : starting dose 260 mg/m2/d (Max. 400 mg)~* Imatinib dose adjustment : Dose is adjusted according to the guidelines if there is serious adverse event, toxicity, or intolerance.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Fabry's Disease and Pregnancy (PREFAB)

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: OTHER
- Primary Purpose: None
- Time Perspective: RETROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Fabry's disease patients, aged 18 years or more, having had at least one childbirth~Exclusion Criteria:~* Patient under a legal protection procedure~* Patient denying to participate to the study~* Lack of affiliation to a social security system

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 45 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Genetic Basis for Prediction of Non-responders to Dietary Plant Sterol Intervention

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: TRIPLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Fasting LDL-C concentration \>3.0 and \<4.9 mmol/L~* Fasting glucose concentration \<6.1 mmol/L~* Fasting triglyceride concentration \<4.52 mmol/L~* Genoset required: ; ApoE ε3/ε3 CYP7A1 rs3808607 T/T (n=20); ApoE ε3/ε3 CYP7A1 rs3808607 G/- (n=22); ApoE ε4/- CYP7A1 rs3808607 -/- (n=22)~Exclusion Criteria:~* Consuming, or have consumed in the last 3 months, medications or nutritional supplements which are known to affect lipid metabolism (such as cholestyramine, colestipol, niacin, clofibrate, gemfibrozil, probucol, HMG-CoA R inhibitors, methotrexate, high dose dietary supplements, fish oil capsules or plant sterol or stanol), or have any dietary restrictions which would prevent them from consuming the trial treatments~* BMI \>40~* Must not have self-reported weight gain or loss greater than 3 kg in the past three months~* Phytosterolemic~* History of active cardiovascular disease including stroke, congestive heart failure, myocardial infarction, unstable angina pectoris, coronary artery bypass graft, percutaneous transluminal coronary angioplasty, temporal ischemic attacks, anemia, abnormal electrolytes, proteinuria, and abnormal liver, kidney or thyroid function~* Type 1 or type 2 diabetes, a history of cancer or malignancy in the last 5 years, or any metabolic disease, gastrointestinal disorder or other clinically significant disease/disorder which could interfere with the results of the study or the safety of the participant.~* Uncontrolled hypertension having systolic blood pressure \>160mm Hg or diastolic blood pressure \>100mm Hg~* Smoker, tobacco/snuff/nicotine users, recreational drug users~* Consume more than 14 alcoholic beverages a week~* Participants who are pregnant or plan to become pregnant during the trial period or lactating mothers~* Participants will be excluded if they have clinically significant biochemistry defined as: LDL-C \<3.0mmol/L or \>4.9 mmol/L; TC \> 6.2 mmol/L; fasting glucose: \> 6.1 mmol/ l, fasting TG \>4.52 mmol/L; AST \>100 U/L; ALT \>100 U/L or or any other clinically significant abnormality in hematology and/or biochemistry at the investigator's discretion~* Patients with unstable or serious illness, for example, dementia, terminal illness, recent bereavement, recent significant medical diagnosis will also be excluded

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: t

Study Arms:
- Plant sterols (Type: ACTIVE_COMPARATOR): None
- Placebo (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: PRODIGY Registry in NYHA Class III Heart Failure Patients

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: CASE_ONLY
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~1. Subject has given written informed consent~2. Male or female complex CCM eligible patients or equivalent and at least 18 years of age~3. Diagnosis of HF ≥ 3 months and NYHA Class III HF at the time of Screening~4. Subject fluent in English (written and oral) and with sufficient eyesight, hearing, and mental capacity to respond to the Cordella™ Heart Failure System audio/visual cues and operate the Cordella™ Heart Failure System~5. Subject has sufficient Cellular and/ or Wi- Fi Internet coverage at home~6. Subject agrees:~   1. that the treating Investigator is their solely complex CCM physician~  2. to return to the treating Investigator for all scheduled follow up visits and can return to the hospital for follow up~Exclusion Criteria:~1. Subjects enrolled in another investigational trial.~2. Subjects who are unwilling or deemed by the Investigator to be unwilling to comply with the study protocol, or subjects with a history of non-compliance~3. Severe illness, other than heart disease, which would limit survival to \<1 year

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Arm (Type: None): Cordella™ Heart Failure System

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Oral Carnitine for Cramps in Pregnancy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Age 16 or older~* Gestational Age 12 to 33 weeks~* Occurrence of muscle cramps at least once weekly~* Ability to tolerate oral L-Carnitine~* Ability / willingness to provide informed consent in English or Spanish~Exclusion Criteria:~* Prior treatment for muscle cramps during this pregnancy~* Chronic muscle cramps prior to pregnancy~* Magnesium administration beyond that contained in prenatal vitamins~* History of seizures~* History of Pre-term delivery before 36 weeks gestational age~* Inability to tolerate oral L-Carnitine (e.g. hyperemesis gravidarum)~* Inability or unwillingness to provide informed consent

- Gender: FEMALE
- Minimum Age: 16 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- I (Type: EXPERIMENTAL): Oral L-Carnitine, 1g PO twice daily
- II (Type: PLACEBO_COMPARATOR): Placebo, similar in appearance to experimental drug, given orally twice daily.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Risk Factors and Biomarkers Associated With Recurrence After Excision of Primary Pterygium

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Clinical diagnosis of primary and recurrence pterygium~* Must agree to participate in this study~* Must sign informed consent form~Exclusion Criteria:~* Hepatitis~* HIV/AIDS

- Gender: ALL
- Minimum Age: 21 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Evaluation of Long-Term Gait Development in Infants With Neonatal Encephalopathy Using Infant Treadmill

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Gestational age \< 33W;~2. Correction of gestational age \< 3 months;~3. It has been diagnosed as hypoxic-ischemic encephalopathy, periventricular intraventricular hemorrhage, periventricular leukomalacia, bilirubin encephalopathy, persistent hypoglycemia and cerebral infarction.~4. There was no other therapeutic intervention before entering the study;~5. Informed consent is signed by the family.~Exclusion Criteria:~1. Brain injury caused by central or peripheral infection (cerebrospinal fluid positive / torch test positive / three major conventional culture positive);~2. Brain damage caused by convulsion;~3. Metabolic brain damage caused by genetic defects;~4. Suffering from known severe congenital malformations;~5. Definite head trauma during labor or postpartum;~6. Peripheral neuromuscular disease or abnormal skeletal system.

- Gender: ALL
- Minimum Age: None
- Maximum Age: 3 Months
- Healthy Volunteers: f

Study Arms:
- intervention group (Type: EXPERIMENTAL): Baby treadmill + conventional physical rehabilitation training
- positive control group (Type: ACTIVE_COMPARATOR): Conventional physical rehabilitation training only

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Pilot Study of Pioglitazone for the Treatment of Moderate to Severe Asthma in Obese Asthmatics (Glitz Asthma)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Asthma diagnosed by a physician at least 1 year prior to study enrollment~* Poorly-controlled asthma at study enrollment~* Non smokers (stopped smoking at least 1 year ago) and limited lifetime history of smoking~* Body mass index 30-60~* Responds to methacholine challenge test with PC20 of \<16 mg/ml~* On a stable dose of inhaled corticosteroid for at least 4 weeks prior to study entry~* FEV1 \> 60% predicted~* Able to obtain weekly weights at home~Exclusion Criteria:~* Systemic steroids within the past 4 weeks~* Lung pathology other than asthma~* Other significant non-pulmonary co-morbidities such as: coronary artery disease, peripheral vascular disease, cerebrovascular disease, congestive heart failure with an ejection fraction \<50%, liver disease or elevated liver enzymes at baseline, malignancy (excluding non-melanoma skin cancers), AIDS, renal failure with serum creatinine \>3.0, or disorders requiring steroid treatment such as vasculitis, lupus, rheumatoid arthritis~* B-type natriuretic peptide (BNP) \>400pg/ml~* Pregnant or lactating~* Currently taking a beta blocker, a CYP2C8 inhibitor or inducer such as gemfibrozil or rifampin, a TZD (thiazolidinedione), or allergic to TZD~* Taking antioxidants (if taking a multivitamin must be on a stable regimen prior to enrollment)~* Illicit drug use within the past year~* Current/active upper respiratory infection (if active URI, wait until asymptomatic for 1 week to enroll)~* Asthma exacerbation within the past 4 weeks (includes ER, urgent care, or hospital visits due to asthma resulting in an increase in asthma-related medications)~* Undergoing evaluation for sleep apnea, or plans to institute treatment for sleep apnea (patients on a stable treatment regimen for sleep apnea for the last 3 months will be allowed to participate)~* Clinically significant abnormalities present on screening 12-lead electrocardiogram~* Women of childbearing potential using oral contraceptives who are not willing to use a second method of contraception during the study

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 60 Years
- Healthy Volunteers: f

Study Arms:
- 1 (Type: ACTIVE_COMPARATOR): None
- 2 (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: safety issues
Please assess the completion status of the following clinical trial:

Trial Title: Release of Acetylcholine From the Ganglionated Plexus During the Thaw Phase of Cryoballon Pulmonary Vein Ablation (GP RESPONSE Study)

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: CASE_ONLY
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* patients with atrial fibrillation undergoing first time cryoballoon ablation~* age 18-80~Exclusion Criteria:~* any prior left atrial ablation or cardiac surgery~* hemoglobin level of \<12.0 g/dL~* refusal or inability to provide informed consent

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Monocentric Study on Acetabulum Patient-specific Pin Drilling Guides

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Is selected to undergo a primary THR~* Informed consent~Exclusion Criteria:~* Is unable to undergo CT imaging of the full pelvis~* Requires surgical treatment within less than 4 weeks of initiation~* Is unable to undergo a THR through a anterolateral approach~* Presents acute/chronic local or systemic infection~* Is allergic to polyamide~* Patient's BMI \> 35~* Patients with severe wear of the acetabular rim or other disorders that affect acetabular rim anatomy and bony landmark recognition.Patients exhibiting severe wear.~* Has impaired decision-making capacity~* Is a prisoner~* Is pregnant~* Has metal components that will result in scatter on the CT imaging

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- THR with conventional technique (Type: ACTIVE_COMPARATOR): Use of conventional technique in THR
- THR with ACOG (Type: EXPERIMENTAL): THR with Acetabular Cup Orientation Guides (ACOG)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues